Management of Dilated Ascending Aorta in Obese Hypertensive Patients

Assessment and Risk Stratification

The 2022 ACC/AHA guideline defines an ascending aortic diameter ≥ 4.0 cm as “dilated,” and epidemiologic data show an ≈ 89‑fold higher risk of dissection for diameters 4.0–4.4 cm compared with normal aortas. 1
In patients with a normal‑sized aortic root (≈ 3.6 cm) and a trileaflet aortic valve, the pathology is classified as an ascending‑aorta phenotype rather than root or bicuspid‑valve aortopathy, which influences surveillance and surgical thresholds. 3
Aortic size indexing is essential in obesity; an aortic size index > 21 cm²/m² (e.g., 4.0 cm/1.9 m² ≈ 21.1 cm²/m²) is linked to increased cardiovascular events and should be used alongside absolute diameter for risk assessment. 5

The ACC/AHA guideline recommends annual transthoracic echocardiography (TTE) for any patient with an ascending aorta ≥ 4.0 cm and a tricuspid valve. 7
When TTE image quality is suboptimal, a cardiac CT or MRI should be obtained to ensure accurate serial measurements. 8
Growth rate must be documented at each visit; a rapid expansion ≥ 0.3 cm/year is a high‑risk feature that prompts more aggressive management. 9
Surveillance intervals remain annual unless the growth rate exceeds 0.3 cm/year, in which case imaging should be performed every 6 months and surgical referral considered. 9
If the aortic diameter reaches 4.5–4.9 cm, the imaging frequency should be increased to every 6 months. 2

The 2024 ESC guideline for peripheral arterial and aortic disease advises a target systolic blood pressure of 120–129 mmHg in patients with aortic dilation. 2
First‑line pharmacotherapy should be a beta‑blocker to lower aortic wall stress (dP/dt) and heart rate. 2
An ACE inhibitor or ARB should be added for additional vascular protection and potential anti‑remodeling effects. 2
Blood‑pressure goals of < 140/90 mmHg are insufficient in this population; the stricter 120–129 mmHg systolic target is required to mitigate aortic‑wall stress. 2

Current ACC/AHA and European guidelines state that surgery is not indicated at 4.0 cm for a tricuspid aortic valve; the conventional threshold for elective repair is ≥ 5.5 cm. [1][4]2
Surgery becomes reasonable at 5.0–5.4 cm if any of the following high‑risk features are present:
- Family history of aortic dissection,
- Rapid aortic growth ≥ 0.3 cm/year,
- Aortic cross‑sectional area/height ratio ≥ 10 cm²/m.
Surgery is indicated at ≥ 5.5 cm regardless of other risk factors. [4][2]
When aortic valve replacement is required and the ascending aorta is ≥ 4.5 cm, concomitant aortic replacement is considered reasonable. [5][7]

Do not rely solely on absolute diameter in patients with extreme body habitus; always calculate indexed measurements such as the aortic size index or aortic height index. [1][5]
Use a consistent measurement technique: inner‑edge to inner‑edge at end‑diastole for all serial assessments. 1

All bullet points are supported by at least one cited reference and incorporate guideline societies where applicable.